MarginsXMarginsX
Home › Markets › Health Care › APVO

Aptevo Therapeutics Inc. (APVO)

APVO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5486
-7.66% on the day
Market cap
$1.5M
Nano cap
Revenue · 2022
$3.1M
-74.7% on 2021
Net income · 2022
$8.0M
257.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/0000950170-24-025428-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerAPVO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001671584
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2022

LineValue
Revenue$3.1M
Net income$8.0M
Operating income-$28.6M
Net margin257.8%
Operating margin-919.7%
Revenue growth-74.7%
Cash$22.6M
Total assets$34.2M
P/E (computed)0.2×
P/S (computed)0.5×

Warning signs

Cash runway
4.6 months
$9.8M cash at June 30, 2026
Share count, 1 year
+886.5%
2025-08-11 to 2026-08-14 · +9164466.2% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$20K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements."
10-Q 2026-08-14
Cash and burn$9.8M cash; operating cash flow -$6.3M a quarter.Report 2026-06-30
Shares outstanding1,801,970 (2026-08-14); 3,287,918 a year earlier; 11,523,716 three years earlier. 1y figure adjusted for splits (1-for-18 overall); 3y figure adjusted for splits (1-for-586080 overall).Cover page 2026-08-14
Reverse splits, 3 years4; latest 1-for-18 on 2025-12-30Source 2025-12-30
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-10-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, Seattle, Washington, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$6.4M-$5.5M$9.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$6.7M-$8.0M$14.5MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$5.8M-$5.2M$21.6MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2025
2025-09-30
Not filed-$7.5M-$6.7M$21.1MNo debt tagsNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$6.2M-$7.1M$9.4MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$6.4M-$6.6M$2.1MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$6.3M-$5.8M$8.7MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2024
2024-09-30
Not filed-$5.1M-$5.2M$7.8MNo debt tagsNeeds four quarters10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-30
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyPRE 14A2026-11-12

Source: SEC EDGAR submissions feed, 747 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-52.1%
1 month-65.7%
3 months-82.5%
Year to date-93.7%
1 year-97.7%
From 52-week high-97.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KAPAKairos Pharma Ltd.$0.4069-10.30%$1.4M
ARTLArtelo Biosciences Inc.$1.70-17.87%$1.6M
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
ENLVEnlivex Ltd.$1.12-5.88%$1.7M
SXTP60 Degrees Pharmaceuticals Inc.$0.4938-4.65%$1.7M
HCWBHCW Biologics Inc.$0.8000+3.48%$1.8M
BDRXBiodexa Pharmaceuticals plc American Depositary Shs$2.24-6.28%$1.2M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier